Letter
Advances in Cardio-Oncology: The Emerging Role of Sglt2 Inhibitors in Cardioprotection
Issue:
Volume 12, Issue 6, December 2024
Pages:
93-97
Received:
17 October 2024
Accepted:
7 November 2024
Published:
29 November 2024
DOI:
10.11648/j.ajbls.20241206.11
Downloads:
Views:
Abstract: Background: The cardiotoxic effects of anti-tumor therapies represent a critical concern in oncology, as they compromise patient survival and quality of life by inducing cardiovascular diseases. With an increasing number of cancer patients undergoing treatments such as chemotherapy and radiation, the incidence of cardiotoxicity has surged. These adverse effects underscore the necessity of early detection, risk stratification, and preventive strategies tailored to mitigate cardiotoxicity and improve patient outcomes. Objective: This meta-analysis aims to systematically evaluate the effectiveness of various interventions designed to prevent or reduce cardiotoxicity associated with anti-tumor therapies. By synthesizing evidence from existing studies, we seek to identify the most effective measures, providing a comprehensive overview of the current landscape in cardioprotective strategies. Methods: We conducted a comprehensive literature search, including peer-reviewed studies that investigated preventive strategies for cardiotoxicity in patients undergoing anti-tumor therapy. Inclusion criteria were studies evaluating pharmacological and non-pharmacological interventions and their effects on cardiac function and patient outcomes. Data were extracted and analyzed to assess the impact of interventions on cardiotoxicity incidence, cardiac biomarkers, and clinical endpoints. Main Findings: Our analysis demonstrates a range of effective cardioprotective interventions, particularly focusing on beta-blockers, ACE inhibitors, and lifestyle modifications. Beta-blockers were found to reduce the incidence of left ventricular dysfunction, while ACE inhibitors showed promise in improving cardiac biomarkers. Additionally, lifestyle interventions, including exercise and dietary modifications, contributed to overall cardiovascular health, though further research is needed to define optimal protocols. Conclusion: Preventive strategies play a pivotal role in managing cardiotoxicity in cancer patients undergoing anti-tumor therapies. Pharmacological interventions, especially beta-blockers and ACE inhibitors, show significant potential in mitigating cardiac damage, while lifestyle interventions offer supplementary benefits. Our findings underscore the importance of an integrative approach, combining pharmacological and lifestyle modifications to protect cardiac function. Future research should focus on personalized cardioprotective protocols to optimize outcomes for cancer patients, ensuring that cardiovascular health is maintained alongside effective anti-tumor treatment.
Abstract: Background: The cardiotoxic effects of anti-tumor therapies represent a critical concern in oncology, as they compromise patient survival and quality of life by inducing cardiovascular diseases. With an increasing number of cancer patients undergoing treatments such as chemotherapy and radiation, the incidence of cardiotoxicity has surged. These ad...
Show More
